Press Releases and Articles

• July 2008

  Camping out for biotech tax credits

• June 2008

  Sequella, Inc. Selected to Present at the 2008 BIO International Convention (pdf)

• April 2008

  Sequella Celebrates a Decade Of Success — Science Highlights Include Advances in Tuberculosis Detection and Treatment (pdf)

• March 2008

  NIAID Statement on World Tuberculosis Day (pdf)

• October 2007

  Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status from the US FDA and Orphan Medicinal Product Designation from the European Medicines Agency for the Treatment of Tuberculosis (pdf)

• July 2007

  Sequella and Chembio Receive Marketing Approval for New Rapid Detection Diagnostic of Tuberculosis (TB) in Non-Human Primates (pdf)

• May 2007

  Sequella Lead Drug SQ109 Completes Phase 1A Trial (pdf)

  Sequella to Present to Investors During BIO International Convention and Business Forum (pdf)

• April 2007

  Sequella Drug Candidate SQ109 Named as One of 100 Great Investigational Drugs in R&D Directions Article (pdf)

  Dr. Carol Nacy Receives Clinical Trials Award at Women in Bio’s 5th Annual Entrepreneur Dinner (pdf)

• March 2007

  Sequella to present at BIO-Europe Spring 2007 (pdf)

  Sequella Receives U.S. Patent for Translocase Inhibitor Drug Compounds (pdf)

• January 2007

  Sequella Receives FDA Fast Track Status for TB Drug (pdf)

  Dr. Nacy, Sequella CEO, to be featured speaker at Women in Bio 2007 executive forum (pdf)

• December 2006

  Science Stops for No Holiday (Washington Post)

• November 2006

  Sequella executive 'focused' on cures (Washington Times)

• October 2006

  Sequella Signs Partnership with Path for TB Patch Clinical Evaluation (pdf)

  Sequella Hires Chief Medical Officer (pdf)

  Sequella Initiates Phase I Clinical Trial for SQ109 (pdf)

• September 2006

  TB in the Headlines: Dangerous new TB strains arriving in U.S. (MSNBC)

  Sequella Releases Clinical Dose-Finding Study Results for TB Patch Diagnostic (pdf)

  Sequella to Present at 2006 ICAAC Conference (pdf)

  Drug-resistant TB on the rise in U.S. (MSNBC)

  Sequella Presents at Merriman Curhan Ford and Company Investor Summit (pdf)

  Dr. Nacy to Receive Leadership Award (pdf)

  Sequella Lead Drug Candidate SQ109 to Begin Clinical Testing in Phase 1 Trial (pdf)

• August 2006

  Sequella Receives Phase 1 SBIR Grant for Translocase I Inhibitors (pdf)

• May 2006

  Sequella Announces Publication of New Diamine Compounds (pdf)

• April 2006

  Sequella and NIH Sign World-Wide Licensing Agreement (pdf)

• January 2006

  Sequella Receives U.S. Patent for Transdermal Patch Diagnostic (pdf)

  Sequella Hires Director of Finance (pdf)

• December 2005

  Sequella Presentation at the 45th ICAAC Meeting, Washington, DC (pdf)

• October 2005

  Sequella Receives U.S. Patent for Novel Therapeutic Compounds (pdf)

  Sequella Presentation at the 36th IUATLD World Conference on Lung Health (pdf)

• August 2005

  Sequella Tackles TB Epidemic, The Business Gazette (pdf)

  Sequella Announces Data Presentation at the 2005 Gordon Research Conference on TB Drug Development (pdf)